1. Home
  2. WMK vs MLYS Comparison

WMK vs MLYS Comparison

Compare WMK & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weis Markets Inc.

WMK

Weis Markets Inc.

HOLD

Current Price

$70.68

Market Cap

1.8B

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$27.46

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WMK
MLYS
Founded
1912
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.2B
IPO Year
1994
2023

Fundamental Metrics

Financial Performance
Metric
WMK
MLYS
Price
$70.68
$27.46
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$48.67
AVG Volume (30 Days)
112.3K
909.5K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
1.96%
N/A
EPS Growth
N/A
37.43
EPS
1.13
N/A
Revenue
$4,714,573,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$62.75
N/A
Revenue Growth
0.01
N/A
52 Week Low
$59.99
$12.59
52 Week High
$79.05
$47.65

Technical Indicators

Market Signals
Indicator
WMK
MLYS
Relative Strength Index (RSI) 52.35 44.27
Support Level $67.90 $26.85
Resistance Level $73.21 $31.12
Average True Range (ATR) 2.04 1.58
MACD -0.00 -0.24
Stochastic Oscillator 33.73 31.23

Price Performance

Historical Comparison
WMK
MLYS

About WMK Weis Markets Inc.

Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: